E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10017764 |
E.1.2 | Term | Gastric cancer stage II |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10017765 |
E.1.2 | Term | Gastric cancer stage III |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10017768 |
E.1.2 | Term | Gastric cancer stage IV without metastases |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess activity of concurrent EOC and Pmab in study patients, measured by proportion of patients with stage T0 and T1 after neoadjuvant study treatment, according to oesophago-gastroscopic endosonography. To assess the tolerability / feasibility of concurrent EOC and Pmab in study patients, measured by proportion of patients with grade 4 diarrhea. |
|
E.2.2 | Secondary objectives of the trial |
To assess: •activity of study treatment, measured by proportion of patients with com-plete (R0) tumour resection and patients with downstaging of their disease during study treatment, according to oesophago-gastroscopic endosonography •the rate of pathologic complete responses in referred to surgery after completion of study treatment •progression-free survival and overall survival 12 months after surgery / end of study treatment •the rate of both treatment-related and –unrelated (severe) adverse events in study patients, measured by CTCAE grades •the tolerability / feasibility of concurrent EOC and Pmab in study patients, measured by proportion of patients completing 3 cycles of concurrent EOC and Pmab |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•Signed informed consent •untreated, histologically confirmed, non-metastasizing, resectable gastric or esophageal adenocarcinoma •KRAS wild type tumor •T2-4 NX M0 disease – see appendix 5 •ECOG performance status 0 or 1 •Patiente 18 to 65 years old •Ability to understand and comply with requirements of study protocol and trial partici-pation •Patients of either sex are eligible for study entry. Women of childbearing potential must have a negative pregnancy test at screening and must use effective contraception (e.g. intrauterine device (IUD), birth control pills, or barrier device) during treatment and for 6 months following the last dose of Pmab.
|
|
E.4 | Principal exclusion criteria |
•Pregnant or breast feeding women. •Women of child-bearing potential and men not willing to use effective contraception during treatment and for 6 months after the end of treatment with Pmab •Previous malignancy other than gastric cancer in the last 5 years except curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix. •Active bacterial, viral or fungal infection (including acute or chronic-active infection with HBV or HCV). •Arterial or venous thromboembolism within 6 months before enrollment •Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) <=1 year before enrollment •History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
To assess activity of concurrent EOC and Pmab in study patients, measured by proportion of patients with stage T0 and T1 after neoadjuvant study treatment, according to oesophago-gastroscopic endosonography. To assess the tolerability / feasibility of concurrent EOC and Pmab in study patients, meas-ured by proportion of patients with grade 4 diarrhea. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 63 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |